Home Tags Solid Tumors

Tag: Solid Tumors

ASCO 2020 – Advancing Antibody-drug Conjugates: Sacituzumab Govitecan

With a growing number of antibody-drug conjugates being approved by regulatory agencies around the world and promising clinical benefits seen in investigational agents, the...

Updated Analysis from Ongoing Phase I Trial of DS-8201 Confirms Significant...

About one in five breast cancers overexpress HER2, a tyrosine kinase receptor growth-promoting protein found on the surface of some cancer cells, which is...

Tisotumab vedotin Demonstrates Encouraging Response Rate and a Manageable Safety Profile...

Preliminary clinical data for tisotumab vedotin, also known as HuMax®-TF-ADC from a Genmab-sponsored phase I/II clinical trial (GEN 701) were featured today in an...

Phase I Clinical Trial of Radioimmunotherapeutic FF-21101 Initiated in Patients with...

Earlier this week Strategia Therapeutics, an integrated pharmaceutical company, announced that it had initiated a Phase I clinical trial of Fujifilm's radioimmunotherapeutic agent FF-21101 (90Y) in...

Compugen’s Antibody Drug Conjugate Program Results Presented

This week, during the World ADC Summit being held October 19 - 22, 2015 in San Diego, CA, Compugen presented the status of its predictive...

Antigen Shedding and Targeted Delivery of Immunotoxins in Solid Tumors: A...

Cells modulate responses to signals in the extracellular environment by shedding cell surface antigens. Understanding this process is important because antibody-based anti-cancer therapies target...